Immutep Reports Nearly 61% Response Rate, 90% Disease Control Rate in Non-Squamous Non-Small Cell Lung Cancer Trial
MT Newswires Live
May 15
Immutep (ASX:IMM) reported a 60.8% response rate and 90.2% disease control rate in the Insight-003 trial, according to a Thursday filing with the Australian bourse.
The trial is evaluating eftilagimod alpha in combination with anti-PD-1 therapy, Keytruda, and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer, the filing said.
The overall response rate in all evaluable patients showed a "significant" improvement compared with historical control from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous non-small cell lung cancer, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.